v3.26.1
Related party transactions (Detail Narrative) - CAD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jun. 24, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Statement [Line Items]        
Research and development expense   $ 3,179 $ 3,081 $ 2,406
CanAm Bioresearch Inc. [Member]        
Statement [Line Items]        
Consideration amount $ 100   100  
Assets transactionsdescription (i) the sale or transfer of all or substantially all of the Assets to a third party purchaser who is not an affiliate of Medicure; (ii) any license to develop, commercialize, use, offer for sale, sell, import, export or exploit P5P Analogues up to a maximum value payable to CanAm of $20,000 and (iii) the sale of an United State Food and Drug Administration priority review voucher obtained in connection with the development of P5P Analogues      
First investigational new drug application $ 500      
First New Drug Application 250      
Net amount $ 500      
Genesys Venture Inc [Member]        
Statement [Line Items]        
Research and development expense   31 5 7
Accounts payable and accrued liabilities   107 32  
Services expense   85 85 85
Rental expense   222 222 222
Commercial And Information Technology   44 44 36
Clinical research services   $ 468 $ 439 318
Key management personnel of entity or parent [member]        
Statement [Line Items]        
Voting shares of Directors and key management personnel control   27.00% 27.00%  
Bottom [Member]        
Statement [Line Items]        
Other Fee And Commission Expense   $ 18    
Bottom [Member] | Chief Financial Officers [Member]        
Statement [Line Items]        
Other Fee And Commission Expense   14 $ 11 $ 10
Top [Member]        
Statement [Line Items]        
Other Fee And Commission Expense   $ 22    
Top [Member] | Chief Financial Officers [Member]        
Statement [Line Items]        
Other Fee And Commission Expense     $ 13